NEW YORK – Abionic announced today it has partnered with Genentech to develop and distribute its in vitro diagnostic asthma test panel in the US.

Under the agreement, Abionic will lead the development process, while Genentech, which is part of Roche, will fund the clinical and regulatory costs of the test. Financial and other terms of the deal were not disclosed.

The test will be performed using Abionic's point-of-care AbioScope device, which is powered by nanofluidic technology.